Your browser doesn't support javascript.
loading
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson, Paul G; Kumar, Shaji K; Masszi, Tamás; Grzasko, Norbert; Bahlis, Nizar J; Hansson, Markus; Pour, Ludek; Sandhu, Irwindeep; Ganly, Peter; Baker, Bartrum W; Jackson, Sharon R; Stoppa, Anne-Marie; Gimsing, Peter; Garderet, Laurent; Touzeau, Cyrille; Buadi, Francis K; Laubach, Jacob P; Cavo, Michele; Darif, Mohamed; Labotka, Richard; Berg, Deborah; Moreau, Philippe.
Afiliación
  • Richardson PG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Masszi T; 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
  • Grzasko N; Department of Experimental Haematooncology, Medical University of Lublin, Lublin, Poland.
  • Bahlis NJ; Center of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland.
  • Hansson M; Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada.
  • Pour L; Department of Hematology, Skåne University Hospital, Lund, Sweden.
  • Sandhu I; Sahlgrenska Academy, Göteborg, Sweden.
  • Ganly P; Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Baker BW; Cross Cancer Institute, University of Alberta, Edmonton, Canada.
  • Jackson SR; Department of Haematology, Christchurch Hospital, Christchurch, New Zealand.
  • Stoppa AM; Department of Haematology, Palmerston North Hospital, Palmerston North, New Zealand.
  • Gimsing P; Department of Haematology, Middlemore Hospital, Auckland, New Zealand.
  • Garderet L; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
  • Touzeau C; Department of Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Buadi FK; Hôpital Pitié-Salpêtrière, Paris, France.
  • Laubach JP; University Hospital Hôtel Dieu, Nantes, France.
  • Cavo M; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Darif M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Labotka R; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • Berg D; Millennium Pharmaceuticals Inc, Cambridge, MA.
  • Moreau P; Millennium Pharmaceuticals Inc, Cambridge, MA.
J Clin Oncol ; 39(22): 2430-2442, 2021 08 01.
Article en En | MEDLINE | ID: mdl-34111952
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Marruecos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Marruecos Pais de publicación: Estados Unidos